Pre-Conference Workshops

Workshop A

Seeking Blood-Based Biomarkers of Neurodegeneration

Tuesday 21st May | 10.00-1.00

One of the main challenges preventing the successful development of neurodegenerative therapeutics is the lack of translatable biomarkers available. Efficient and successful blood-based biomarkers would transform the drug development field, from preclinical model studies to patient diagnosis.

Attend this workshop to:

  • Discover the blood-based biomarker technologies available
  • Discuss the need for robust blood-based biomarkers of neurodegeneration
  • Assess precision and fluctuation limitations of biomarker detection
  • Introduce blood-based biomarkers to clinical studies

Workshop Leader:

Ulf Andreasson Photo

Ulf Andreasson
Associate Professor
University of Gothenburg

Workshop B

Evaluating Gene Therapy as a Therapeutic for Neurodegeneration

Tuesday 21st May | 2.00-5.00

Gene therapy has made important advances in the clinic over the last decade. Among neurological diseases, severe genetic neurodegenerative conditions have been the focus of initial clinical applications. Gene therapy has also addressed complex neurodegenerative diseases, particularly Parkinson's disease, with encouraging results in human patients. It demonstrates that specific targeting of central nervous system cells is a relevant strategy for severe pathologies and that efficient access to the CNS with viral vectors is an achievable goal.

Attend this workshop to:

  • Evaluate the gene therapy clinical applications that have been utilised for neurodegenerative diseases
  • Discuss the limitations and challenges faced by gene therapy developers to obtain and demonstrate benefit in patients
  • Review the latest developments that could allow new clinical applications with high beneficial potential

Workshop Leader:

Nathalie Cartier Photo

Nathalie Cartier
Acting Chief Scientific Officer
BrainVectis